In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosite and FivePrime in diagnostics and therapeutics agreement:

This article was originally published in Clinica

Executive Summary

Biosite has teamed up with fellow California firm Prime Therapeutics to evaluate disease targets for potential diagnostic and therapeutic products. Under the collaboration, FivePrime, which has a comprehensive protein discovery programme, will provide Biosite with access to its selected functional disease targets for use in developing diagnostics. In exchange, FivePrime, of San Francisco, will get access to San Diego-based Biosite's Omniclonal antibodies for selected targets to accelerate its therapeutic research efforts.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts